Targeting survivin with Tanshinone IIA inhibits tumor growth and overcomes chemoresistance in colorectal cancer

被引:8
|
作者
Cao, Yaoquan [1 ]
Tang, Haibo [1 ]
Wang, Guohui [1 ]
Li, Pengzhou [1 ]
Song, Zhi [1 ]
Li, Weizheng [1 ]
Sun, Xulong [1 ]
Zhong, Xiaoxiao [1 ]
Yu, Qianqian [1 ]
Zhu, Shaihong [1 ]
Zhu, Liyong [1 ]
机构
[1] Cent South Univ, Xiangya Hosp 3, Dept Gen Surg, Changsha 410013, Peoples R China
关键词
STEM-CELLS; APOPTOSIS; CHEMOTHERAPY; RESISTANCE;
D O I
10.1038/s41420-023-01622-8
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The inhibitor of apoptosis protein survivin has a critical regulatory role in carcinogenesis and treatment tolerance in colorectal cancer (CRC). However, the targeted drugs for survivin protein are extremely limited. In the present research, we discovered that Tanshinone IIA (Tan IIA) played a dual regulatory role in inhibiting tumorigenesis and reversing 5-Fu tolerance via modulating the expression and phosphorylation of survivin in CRC cells. Mechanistically, Tan IIA suppressed the Akt/WEE1/CDK1 signaling pathway, which led to the downregulation of survivin Thr34 phosphorylation and destruction of the interaction between USP1 and survivin to promote survivin ubiquitination and degradation. Furthermore, Tan IIA significantly facilitated chemoresistant CRC cells to 5-Fu sensitivity. These results revealed that Tan IIA possessed a strong antitumor activity against CRC cells and could act as an up-and-coming agent for treating CRC and overcoming chemotherapy resistance.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Targeting survivin with Tanshinone IIA inhibits tumor growth and overcomes chemoresistance in colorectal cancer
    Yaoquan Cao
    Haibo Tang
    Guohui Wang
    Pengzhou Li
    Zhi Song
    Weizheng Li
    Xulong Sun
    Xiaoxiao Zhong
    Qianqian Yu
    Shaihong Zhu
    Liyong Zhu
    Cell Death Discovery, 9
  • [2] Targeting Aurora B kinase with Tanshinone IIA suppresses tumor growth and overcomes radioresistance
    Ming Li
    Haidan Liu
    Qin Zhao
    Shuangze Han
    Li Zhou
    Wenbin Liu
    Wei Li
    Feng Gao
    Cell Death & Disease, 12
  • [3] Targeting Aurora B kinase with Tanshinone IIA suppresses tumor growth and overcomes radioresistance
    Li, Ming
    Liu, Haidan
    Zhao, Qin
    Han, Shuangze
    Zhou, Li
    Liu, Wenbin
    Li, Wei
    Gao, Feng
    CELL DEATH & DISEASE, 2021, 12 (02)
  • [4] Butein promotes ubiquitination-mediated survivin degradation inhibits tumor growth and overcomes chemoresistance
    Xin Dong
    Wenbin Liu
    Xiaoying Li
    Yu Gan
    Li Zhou
    Wei Li
    Li Xie
    Scientific Reports, 12
  • [5] Butein promotes ubiquitination-mediated survivin degradation inhibits tumor growth and overcomes chemoresistance
    Dong, Xin
    Liu, Wenbin
    Li, Xiaoying
    Gan, Yu
    Zhou, Li
    Li, Wei
    Xie, Li
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [6] Author Correction: Butein promotes ubiquitination-mediated survivin degradation inhibits tumor growth and overcomes chemoresistance
    Xin Dong
    Wenbin Liu
    Xiaoying Li
    Yu Gan
    Li Zhou
    Wei Li
    Li Xie
    Scientific Reports, 13
  • [7] Butein promotes ubiquitination-mediated survivin degradation inhibits tumor growth and overcomes chemoresistance (vol 12, 20644, 2022)
    Dong, Xin
    Liu, Wenbin
    Li, Xiaoying
    Gan, Yu
    Zhou, Li
    Li, Wei
    Xie, Li
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [8] Suppression of colorectal tumor growth by regulated survivin targeting
    Binghua Li
    Junkai Fan
    Xinran Liu
    Rong Qi
    Linan Bo
    Jinfa Gu
    Cheng Qian
    Xinyuan Liu
    Journal of Molecular Medicine, 2006, 84 : 1077 - 1086
  • [9] Suppression of colorectal tumor growth by regulated survivin targeting
    Li, Binghua
    Fan, Junkai
    Liu, Xinran
    Qi, Rong
    Bo, Linan
    Gu, Jinfa
    Qian, Cheng
    Liu, Xinyuan
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2006, 84 (12): : 1077 - 1086
  • [10] Tanshinone IIA inhibits cell proliferation and tumor growth by downregulating STAT3 in human gastric cancer
    Zhang, Yongjun
    Guo, Shuguang
    Fang, Jian
    Peng, Bojian
    Zhang, Yuan
    Cao, Tiansheng
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2018, 16 (04) : 2931 - 2937